UNLOCKING A NEW SOURCE OF MICROBES TO IMPROVE HUMAN HEALTH
INSPIRED BY NATURE, POWERED BY SCIENCE
Solarea Bio is a clinical stage biotech company in Waltham MA building health solutions using bacteria and fungi native to healthy foods to create powerful synergistic, anti-inflammatory microbial assemblages backed by clinical validation.
Launched at the Illumina Accelerator in 2017, Solarea has built a powerful computational engine using microbial discovery and genomics to rapidly deliver safe and effective medical food products to address chronic inflammatory conditions.
Solarea Bio is creating a new class of health products by mining the microbes that naturally colonize healthy foods to address inflammatory disorders
Inspired by nature and using computational and experimental approaches, bacteria and fungi are combined with other natural substrates to create functional and specific consortia
Our vision is to create and lead a new way to rapidly discover, develop, and launch commercial products aiding in the management of disorders where existing solutions are not sufficient
News & Press
Ilissa Larimore Appointed Chief Commercial Officer at Solarea Bio
Solarea announces the appointment of Ilissa Larimore as Chief Commercial Officer (CCO). Ilissa joins Solarea Bio with over 20 years of experience in consumer health, personalized wellness and practitioner engagement to help individuals achieve optimal health.
Jun 26 2024
Solarea Bio Announces the Beta Launch of Bondia™, a Novel Daily Medical Food Helping Menopausal Women Manage Bone Loss
The complete beta launch experience, known as the Beta Complete Journey, includes a baseline total body DEXA scan, a year of Bondia™ capsules, and access to an accompanying mobile app.
May 08 2024
The NIH/National Institute on Aging has awarded a R01 $3 million grant to study the impact of a medical food developed by Solarea Bio
Hebrew SeniorLife, United States Department of Agriculture (USDA) Human Nutrition Research Center on Aging (HNRCA) at Tufts University, Maine Medical Center Research Institute, and Solarea Bio are grant recipients
Aug 25 2023
Solarea Bio Announces First Close of Series B Financing Round
Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.
May 08 2023